The diagnosis of giant cell arteritis

Reviews in Neurological Diseases

Volumn 4, Issue 3, 2007, Pages 128-142

  Melson, Mark R ^a   Weyand, Cornelia M ^b   Newman, Nancy J ^a,b   Biousse, Valérie ^a,b  

^a Department of Ophthalmology ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Erythrocyte sedimentation rate; Fluorescein angiography; Giant cell arteritis; Imaging; Temporal artery biopsy

Indexed keywords

ABNORMAL LABORATORY RESULT; BLOOD VESSEL BIOPSY; GIANT CELL ARTERITIS; HUMAN; INFLAMMATION; NEUROOPHTHALMOLOGY; REVIEW; SYMPTOM; SYSTEMATIC REVIEW; VISUAL IMPAIRMENT;

ARTERIES; BIOLOGICAL MARKERS; BLINDNESS; COMORBIDITY; GIANT CELL ARTERITIS; HEADACHE; HUMANS; INTERMITTENT CLAUDICATION; OPHTHALMIC ARTERY; POLYMYALGIA RHEUMATICA; TEMPORAL ARTERIES;

EID: 35148866081     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Hunder GG. Epidemiology of giant-cell arteritis. Cleve Clin J Med. 2002;69(suppl 2):SII-79-SII-82.
2. Piponos II, Hopp R, Edwards WD, et al. Giant-cell temporal arteritis in a 17-year-old male. J Vasc Surg. 2006;43:1053-1055.
3. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778-799.
4. Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis: report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum. 1983;26:1214-1219.
5. Liu NH, LaBree LD, Feldon SE, et al. The epidemiology of giant cell arteritis: a 12 year retrospective study. Ophthalmology. 2001;108:1145-1149.
6. Salvarani C, Gabriel SE, O'Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclical pattern. Ann Intern Med. 1995;123:192-194.
7. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003;139:505-515.
8. Younge BR, Cook BE, Bartley GB, et al. Initiation of glucocorticoid therapy: before or after temporal artery biopsy? Mayo Clin Proc. 2004;79:483-491.
9. Hayreh SS, Podhajsky PA, Raman R, et al. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123:285-296.
10. Gonzales-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41:1497-1504.
11. Font C, Cid MC, Coll-Vincent B, et al. Clinical features inpatients with permanent vision loss due to biopsy-proven giant cell arteritis. Br J Rheumatol. 1997;36:251-254.
12. Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998;125:521-526.
13. Ghanchi FD, Dutton GN. Current concepts in giant cell (temporal) arteritis. Surv Ophthalmol. 1997;42:99-123.
14. Hedges TR, Gieger GL, Albert DM. The clinical value of negative temporal artery biopsy specimens. Arch Ophthalmol. 1983;101:1251-1254.
15. Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum. 2001;45:140-145.
16. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33;1122-1128.
17. Rodriguez-Valverde V, Sarabia JM, Gonzales-Gay MA, et al. Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med. 1997;102:331-336.
18. Niederkohr RD, Levin LA. Management of the patient with suspected temporal arteritis. Ophthalmology. 2005;112:744-756.
19. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287:92-101.
20. Gordon LK, Levin LA. Visual loss in giant cell arteritis. JAMA. 1998;280:385-386.
21. Kyle V, Cawston TE, Hazleman BL. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis. 1989;48:667-671.
22. Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed). 1983;286:266.
23. Hanger WA, Sainsbury R, Gilchrist NL, et al. Erythrocyte sedimentation rates in the elderly: a community study. NZ Med J. 1991;104:134-136.
24. Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998;41:26-32.
25. Gonzales-Gay M, Lopez-Diaz M, Barros S, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine. 2005;84:277-290.
26. Eashagian J, Goeken JA. C-reactive protein in giant cell (cranial, temporal) arteritis. Ophthalmology. 1980;87:1160-1166.
27. Parikh M, Miller NR, Lee AG, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006;113:1842-1845.
28. Hunder GG. Giant cell arteritis and polymyalgia rheumatica. In: Ruddy S, Harris ED, Sledge BC, et al, eds. Kelley's Textbook of Rheumatology, 6th ed. Philadelphia, PA: WB Saunders Company; 2001:1155-1164.
29. Bergstrom AL, Bengtsson BA, Olsson LB, et al. Thrombokinetics in giant cell arteritis, with special reference to corticosteroid therapy. Ann Rheum Dis. 1979;38:244-247.
30. Krishna R, Kosmorsky GS. Implications of thrombocytosis in giant cell arteritis. Am J Ophthalmol. 1997;124:103.
31. Lincoff NS, Erlich PD, Brass LS. Thrombocytosis in temporal arteritis. Rising platelet counts: a red flag for giant cell arteritis. J Neuroophthalmol. 2000;20:67-72.
32. Foroozan R, Danesh-Meyer H, Savino PJ, et al. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2002;1009:1267-1271.
33. Costello F, Zimmerman MB, Podhajsky PA, et al. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol. 2004;14:245-257.
34. Holdstock G, Mitchell JRA. Erythrocyte sedimentation rate before and after in-vitro defibrination: a rapid and simple method for increasing its specificity. Lancet. 1977;2:1314-1316.
35. Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis. Arth Rheum. 2000;43:1041-1048.
36. Allsop CJ, Gallagher PJ. Temporal artery biopsy in giant cell arteritis: a reappraisal. Am J Surg Pathol. 1981;5:317-323.
37. Buchbinder R, Detsky AS. Management of suspected giant cell arteritis: a decision analysis. J Rheumatol. 1992;19:1220-1228.
38. Wells KK, Folberg R, Goeken JA, et al. Temporal artery biopsies. Correlation of light microscopy and immunofluorescence microscopy. Ophthalmology. 1989;96:1058-1064.
39. Schmidt D, Loffler KU. Temporal arteritis comparison of histological and clinical findings. Acta Ophthalmol. 1994;72:319-325.
40. Lie JT. Temporal artery biopsy diagnosis of giant cell arteritis: lessons from 1109 biopsies. Anat Pathol. 1996;1:69-97.
41. Albert DM, Ruchman MC, Keltner JL. Skip areas in temporal arteritis. Arch Ophthalmol. 1976;94:2072-2077.
42. Klein RG, Campbell RJ, Hunder GG, et al. Skip lesions in temporal arteritis. Mayo Clin Proc. 1976;51:504-510.
43. Mahr A, Saba M, Kambouchner M, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis. 2006;65:826-828.
44. Kent RB 3rd. Temporal artery biopsy. Am Surg. 1990;56:16-21.
45. Su GW, Foroozan R, Yen MT. Quantitative analysis of temporal artery contraction after biopsy for evaluation of giant cell arteritis. Can J Ophthalmol. 2006;41:500-503.
46. Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Arch Intern Med. 1994;120:987-992.
47. Guevera RA, Newman NJ, Grossniklaus HE. Positive temporal artery biopsy 6 months after prednisone treatment. Arch Ophthalmol. 1998;116:1252-1253.
48. Font RL, Prabhakaran VC. Histologic parameters helpful to recognize steroid-treated temporal arteritis: an analysis of thirty-five cases. Br J Ophthalmol. 2007;19:204-209.
49. Hayreh SS. Anterior ischemic optic neuropathy. Differentiation of arteritic from non-arteritic type and its management. Eye. 1990;4:25-41.
50. Siatkowski RM, Gass JD, Glaser JS, et al. Fluorescein angiography in the diagnosis of giant cell arteritis. Am J Ophthalmol. 1993;115:57-63.
51. Mack HG, O'Day J, Currie JN. Delayed choroidal perfusion in giant cell arteritis. J Clin Neuroophth. 1991;11:221-227.
52. Quillen DA, Cantore WA, Schwartz SR, et al. Choroidal nonperfusion in giant cell arteritis. Am J Ophthalmol. 1993;116:171-175.
53. Sadun F, Pece A, Brancato R. Fluorescein and indocyanine green angiography in arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol. 1998;82:1344-1345.
54. Valmaggia C, Speiser P, Bischoff P, et al. Indocyanine green versus fluorescein angiography in the differential diagnosis of arteritic and nonarteritic anterior ischemic optic neuropathy. Retina. 1999;19:131-134.
55. Schmidt WA, Kraft HE, Vorpahl K, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997;337:1336-1342.
56. Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med. 2002;137:232-238.
57. Karassa FB, Matsagas MI, Schmidt WA, et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005;142:359-369.
58. Bley TA, Wieben O, Uhl M, et al. High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. Am J Roentgenol. 2005;184:283-287.
59. Bley TA, Weiben O, Uhl M, et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum. 2005;52:2470-2477.
60. Bley TA, Uhl M, Venhoff N, et al. 3-T MRI reveals cranial d thoracic inflammatory changes in giant cell arteritis. Clin Rheumatol. 2007;26:448-450.
61. Nuenninghoff DM, Hunder GG, Christianson TJH, et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3532-3537.
62. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med. 1995;122:502-507.
63. Bongartz T, Matteson EL. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol. 2006;18:10-17.
64. Atalay MK, Bluemke DA. Magnetic resonance imaging of large vessel vasculitis. Curr Opin Rheumatol. 2001;13:41-47.
65. Stanson AW. Imaging findings in extracranial (giant cell) temporal arteritis. Clin Exp Rheumatol. 2000;18(suppl 20):S43-S48.
66. Narvaez J, Narvaez JA, Nolla JM, et al. Giant cell arteritis and polymyalgia rheumatica; usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology. 2005;44:479-483.
67. Bley TA, Wieben O, Uhl M, et al. Integrated head-thoracic vascular MRI at 3T: assessment of cranial, cervical and thoracic involvement in giant cell arteritis. MAGMA. 2005;18:193-200.
68. 18F]FDG PET and MRI. Eur J Nucl Med Mol Imaging. 2003;30:730-736.
69. Agard C, Ponge T, Hamidou M, et al. Role for vascular investigations in giant cell arteritis. Joint Bone Spine. 2002;69:367-372.
70. Hervé F, Choussy V, Janvresse A, et al. Aortic involvement in giant cell arteritis: a prospective follow-up of 11 patients using computed tomography [in French]. Rev Med Interne. 2006;27:196-202.
71. Tso E, Flamm SD, White RD, et al. Takayashu arteritis. Utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum. 2002;46:1634-1642.